|
Stayin' Alive (1)
The pharma industry can be strange. In the latest example, a drug company is trying to figure out what to do with their clinical trial now that people aren’t dying fast enough.
Pre-trial, of the 156 patients enrolled, the company estimated 70 would progress or die by July and so that was their trial endpoint. Yet many more than that are still doing well.
Hard times for Ultimovacs.
Stayin' Alive (2)
And in similarly odd news, Exelixis stopped a trial because it was going too well.
Yes, that happens. How it typically goes, is the data become so overwhelmingly positive, it’s considered unethical not to make the treatment available as quickly as possible to interested patients. (And drug companies obviously like the idea of getting paid quicker.)
Good news for those with advanced pancreatic or extra-pancreatic neuroendocrine tumors whose disease has progressed after prior therapy.
Capital Crime
Biotech companies like to mix capital letters into the middle of words. It’s common and even BioPharmGuy is doubly guilty. But there are times when they are inconsistent, and we don’t know what to enter into our directory.
Here we have the case of BioXyTran. Or at least that’s what the logo says. The first paragraph on the page goes with 'Bioxytran'. But scroll down one frame to the video and the title references 'BioxyTran'. The footer of the website brings it back to BioXyTran.
What a mess.
Nurami Medical
This group is working on medical nanofiber technology. They're located in the city of Haifa, which we thought was in Israel, but according to Linkedin it's actually in "Choose a State", which is known for its great vacation spots.
Mr. President
It's normal for Japanese and Korean companies to have a written statement from the CEO/President on the website. What's not common is to sign it “President of _____” and omit the guy's name, but evidently Shin Poon loves breaking barriers.
Biotech Website Archaeology
If you're going to run a family business doing chromatography services, it's a good idea to put forward a professional visage. How not to do that is to keep a website like this hanging around.
The company was active as of 2022, so this style isn't due to a pre-paid website outliving the business.
Fun fact - their latest bit of news from 11 years ago is they reached an agreement with Agilent to be a service provider.
We do our website in-house here at BPG, but it can't be that expensive to have someone make a nice five-pager, can it?
Psych
Despite decades of human use proving their safety, psychedelics just can’t seem to reach the highs expected of investors. Thus, a shakeout is in the offing.
Two companies who couldn’t hack it alone are now combining into a “clear market leader” who will no doubt last for numerous months before inevitably succumbing to the reality of trying to market a schedule 1 drug.
Team Roast - Oh Baby
New startup launched and was desperate for any kind of PR, so they laid a delicious roast on a platter for us - by posting BABY PICTURES of the team.
Can’t really wrap our heads around any scenario where this would make sense. Maybe if the company were targeting pediatrics? (Superluminal is not.)
How awkward was that email from the website guy asking for childhood pictures?
We once jokingly roasted dogs in this space and people did not seem to like it. So, we are not about to roast babies. But please enjoy the headshaking you will engage in as you check out the team.
Nonparenteral Therapies
Orphan drugs are those that are targeting an indication with fewer than 200,000 American patients (224,000 when converted to Euros).
Regulatory agencies allow special consideration for their approval as the market is not considered to be especially lucrative.
What they are not is drugs intended for actual orphans.
But Orphanix seems to have missed the memo because based on the picture on their homepage, they are all in on those 19th century ragamuffins.
| 
